Liphagal (A) is a very potent and selective inhibitor of PI3Kα (p110α) and is under development for an oncolytic drug. We herein report the new and concise synthesis of key intermediates (7, 8), which have been used for liphagal synthesis and will be useful for generating liphagal-based chemical entities for drug discovery purposes.
No takes yet. Share an insight, caveat, or question.
Deore et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: